Interleukin-15 (IL-15) has emerged as a central cytokine for next-generation cancer immunotherapy because of its unique ability to sustain the survival, proliferation, and cytotoxic function of memory CD8<sup>+</sup> T cells and natural killer (NK) cells without promoting the expansion of regulatory T cells (Treg). This evidence concerns the gene CD8A and cancer.